's Information

Jung-Min Ahn , MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. Bicuspid TAVR: All the Technical Issues and Data From Asan Medical Center
  2. Rule of 6-8-12 for Left Main Upfront 2-Stenting
  3. Indirect Assessment of Microvascular Function by Pressure Wire and Its Prognostic Value- Coronary Pressure Reserve
  4. Are We Ready? Completed and Ongoing Trials of Vulnerable Plaque Intervention(PREVENT II)
  5. IVUS Guided LM Bifurcation Treatment
  6. Most Updated Perioperative Antiplatelet Strategy Post-PCI: ASSURE-DES and More
  7. Contrasting Prognostic Value of Discordance Between FFR and NHPR
  8. Imaging Criteria for Determining LM Bifurcation Strategy and Optimizing Stenting
  9. Unmet Need for FFR in Left Main PCI: FATE-MAIN Trial
  10. Optimal Minimal Stent Area and Impact of Stent Under-Expansion in Left Main Stenting
  11. How I Treated the Case
  12. How Would I Treat the Case
  13. Master's Case 1. Ischemic Cardiomyopathy with Multi-vessel Disease
  14. TAVR for Bicuspid AV: What's Different?
  15. VARIANT-ICD Trial: ICD vs. Medical Therapy Alone in Variant Angina With Aborted SCD
  16. FATE-MAIN Trial: FFR- vs. Angiography-guided Left Main PCI
  17. PREVENT Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque
  18. 15 Years History of TAVR in Asan Medical Center: Minimalist Intuitive Simple Approaches
  19. Bicuspid TAVR: All the Technical Issues and Data From Asan Medical Center
  20. Synergetic Approach for Discordant Lesions Between FFR and Non-Hyperemic Indexes
  21. The Fate of Deferred Lesions; Insight From the IRIS-FFR Registry
  22. Rule of 5-6-7-8 for Bifurcation PCI: It Is Time to Change in 2024
  23. Left Main AMI with Cardiogenic Shock, How to Rescue?
  24. Choosing Wisely: FFR vs. Anatomy Dilemma in LM PCI and Introduction to FATE-MAIN Trial
  25. Precision in Stent Sizing: Insights from Imaging-Guided LM PCI
  26. TAVR for Bicuspid AV: What’s Different?
  27. Synergetic Approach for Discordant Lesions Between FFR and Hyperemia Free Indexes
  28. ASSURE-DES Trial
  29. 10-Year Extended Follow-up of BEST Trial
  30. Defining Lesion Severity (by Angiography, Physiology & IVUS)
  31. Not to Treat
  32. Optimal MSA for LM Crush Technique: New Criteria Any Difference in Any 2 Stent Technique?
  33. TAVR Techniques in Bicuspid Anatomy – Valve Selection, Sizing, and Positioning
  34. How to Optimize 1st Valve Choice Matter for Future
  35. How Can We Treat Patients with Concomitant Coronary Artery Disease?
  36. Low Penetration of FFR (1A Class) in Real Practice; Why and How to Overcome?
  37. Case 4. CTO
  38. CTO Revascularization 2022: Guidelines and Concept Change
  39. Physiologic Approach For Non-LM Bifurcation Disease
  40. Unmet Need for FFR in LM PCI
  41. Minimalist TAVI : Achieving Great TAVI Efficiency and Optimal Patient Outcome
  42. 타비 시술을 위한 CT 평가
  43. TAVR for Bicuspid Valve: Practical Tips and Tricks for Optimal Sizing and Positioning
  44. FFR is a Routine Cath Lab Procedure
  45. FFR, It's Standard
  46. The Basics of Coronary Physiology Measurement: FFR, iFR and other NHPRs
  47. Updated Imaging/Physiology-Guided PCI Tuning 2021
  48. Under Pressure: Optimal Post-Dilation Strategy
  49. Difficult Wiring, Tips and Tricks
  50. TAVR for Bicuspid AS: Optimal Sizing & Valve Selection
  51. Imaging-guided PSP for Optimizing PCI
  52. How to Treat Tandem Lesion Under Physiology-Guidance
  53. Guide Extension Catheters: Strong Support from Mother-Child Relationship
  54. Post TAVR Coronary Access with Evolut System
  55. Self-Expandable Evolut R & PRO Valve
  56. TAVR for Bicuspid AV: Tips and Tricks
  57. Bifurcation PCI: Contemporary Practical Approach
  58. The Role of Debulking Atherectomy for Calcific In-stent Restenosis
  59. Prognosis of Discordant Lesion Between FFR and Hyperemia Free Indexes
  60. [Case-based Debate: Intracoronary Imaging Modalities for PCI Guidance] IVUS Is Better!
  61. Clinically Relevant PeriProcedural MI: Practical and Clinical Trial Aspect
  62. Case 1: Unexpanded ISR - Challenging and Optimal Treatment
  63. How Do I Implement?: FFR and Various Non-hyperemic Diastolic Index
  64. Current Status of Balloon-Expandable TAVR in Korea
  65. OAC in TAVR: FAILED GALILEO - NOAC Don't Work or Other Options?
  66. TAVR for Bicuspid AV: Tips and Tricks
  67. Synergetic Approach for Discordant Lesions Between FFR and Hyperemia Free Indexes
  68. Guide Extension Catheters: A Strong Support from a Parent-Child Relationship
  69. Expert Case Review: Complex PCI for Severe Calcified Coronary Disease
  70. Expert Case Review: Complex Bifurcation PCI
  71. Impact of Renal Function on Stroke or Systemic Embolism Following TAVR
  72. TAVR for Bicuspid Valve: Clinical Outcome and Technical Considerations
  73. TAVR: Bicuspid, Severe Calcium, and Low Lying Left Main
  74. TAVR in Bicuspid Aortic Stenosis with Severe Calcification: Case Reviews and Tips-and-Tricks
  75. How About Integrated Use of Resting Pd/Pa and FFR?
  76. Distal Left Main Bifurcation PCI: Concept Is More Important.
  77. [Case #2: Transcatheter Aortic Valve Implantation in a Patient with Type B Aortic Dissection] Part 2. How Would I Treat?
  78. FFR as the Gold Standard Index!
  79. Five-Year Outcomes of Routine FFR Use in Clinical Practice: Data from ASAN PCI Registry
  80. The Benefit of Complete Revascularization in Complex Coronary Artery Disease
  81. Asian Pacific TAVR Registry
  82. [Taped Case] TAVR with Evolut R
  83. Bicuspid AS: Future Perspectives of TAVR
  84. Integrated Use of FFR and IVUS for LM PCI
  85. Bicuspid TAVR Registry and TRANSIT Trial: TAVI Experience in AMC
  86. Bicuspid and Valve-in-Valve; How Different?
  87. Clinical Outcome of DEFER
  88. Left Main and MVD PCI: Imaging and Functional Guidance
  89. Utility of Intravascular Imaging for Resolving Issues During PCI
  90. Long Lesion and Tandem Lesion
  91. Bicuspid TAVR Registry
  92. AP TAVR Registry
  93. Current Status of TAVR: High/Intermediate and Lower Risk
  94. Clinical Impact of Routine FFR Measurement
  95. Tandem
  96. Prognostic Value of FFR: Insight from IRIS-FFR Registry
  97. Practical Aspect of IMR in AMI and Stable Angina
  98. Elderly Population
  99. LM PCI 2016: Integrated Approach Using IVUS, FFR and New Imaging Modality
  100. [Review in 2015] Physiology
  101. Tandem Lesion Evaluation
  102. Integrated Use of IVUS and FFR in Real Practice
  103. Readmission After PCI or CABG
  104. Left Main
  105. Final Answer RESTORE
  106. Comparative Outcomes of Various DES from IRIS-MAIN Registry and PRECOMBAT Series
  107. Case Presentation 4: Medically Stabilized Type A Aortic Dissection After TAVI
  108. Randomzed Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: Five-Year Outcomes of the PRECOMBAT Study
  109. Preliminary Data from IRIS FFR Registry
  110. Complex Lesions, Left Main, Bifurcations, Tandem, and More
  111. Left Main PCI
  112. Understanding About Visual-Functional Mismatching
  113. TAVI for Bicuspid Valve Stenosis
  114. FFR-guided PCI in Routine Practice: Learn from AMC Experiences
  115. Is There a Generation Gap of DES: Results of PRECOMBAT Study Series
  116. Clinical Implementation of FFR
  117. Case-based Review: Incidence and Treatment of LM ISR
  118. LM & Tandem Lesion
  119. VH IVUS: Native Plaque and Neointima
  120. Clinical Evidence of Neoatherosclerosis: ISR and Late Stent Thrombosis
  121. LM PCI
  122. IRIS-ELEMENT Data Review
  123. Cross and Perfect: 2013 Update
  124. Anatomical - Functional Stenosis: How Much Discordant?
  125. Case Presentation: Functional Angioplasty
  126. Impact of Functional Angioplasty on Clinical Outcomes of PCI
  127. Novice's Trial of Complex LM PCI
  128. New-generation DES for Long Lesions: From a Large-scale Cohort Regis
  129. FFR Utilization in LM PCI
  130. Promus Element Clinical Program in Asan Medical Center
  131. FFR-guided PCI in Tandem Lesion
  132. Two Cases with Coronary Thromboembolism
  133. Does the Timing of IABP Matter?
Conference Slides
Category